A pharmaceutical company offers to sponsor your research project but expects to have control over the publication of the results. Discuss the ethical implications and how you would handle this offer.

Where answers to this question lose points

Our scorer marks every answer on three parts. For each of the 238 applicants who finished this question on Confetto, we took their first scored answer and counted the part that scored lowest.

• Structure: a clear order and a clear point93 of 238
• Content: covering what the question needs47 of 238
• Communication: tone, clarity and professionalism34 of 238

Confetto data as of November 8, 2026. A part is shown only when 20 or more applicants share it. Answers where two parts tied are not counted toward either. We never show anyone's answers or details.

What this question tests

• Professionalism

How to structure your answer

1. What it's about (15 seconds). The answer frames the offer as a conflict between securing research funding and protecting scientific integrity, affecting researchers, patients, clinicians, and public trust in medical science.
2. Both sides (40 seconds). The answer acknowledges that industry funding can support research and that companies have legitimate intellectual property interests. Against this, publication control could suppress unfavorable findings or distort their presentation, creating publication bias that undermines clinical decisions and public trust.
3. Your position (20 seconds). The answer prioritizes scientific truth and public benefit, accepting sponsorship only if publication independence is protected. It proposes reviewing the agreement with institutional ethics and legal teams, negotiating publication rights, and declining if the company insists on control.
4. Its downside (15 seconds). The answer recognizes that refusing restrictive funding could delay the project or require a smaller research scope. It would soften that cost by seeking government grants, academic support, or independent foundation funding rather than compromising transparency.
5. What would change it (10 seconds). The answer would reconsider rejecting the sponsorship if the company agreed to protect the researcher's right to publish all results. A reasonable review period for proprietary information would address legitimate company concerns without granting control over publication.
6. Common pitfalls. A flat refusal before considering funding needs and legitimate intellectual property concerns would make the answer one-sided. Remaining vague about publication independence, or allowing sponsor review to become an indefinite veto over unfavorable results, would also weaken it.

Example answer from Confetto

Example answer from Confetto. Not a real applicant's answer.

I recognize this scenario presents a significant ethical dilemma that pits the practical need for research funding against the fundamental principles of scientific integrity and transparency. My immediate concern is that allowing a pharmaceutical company to control publication rights could compromise the integrity of scientific research and potentially harm public trust in medical science.

As a researcher, I believe my primary obligation is to scientific truth and public benefit. While I appreciate the pharmaceutical company's interest in funding my work, I have serious reservations about accepting terms that could allow them to suppress unfavorable results or manipulate the presentation of findings. I've seen how publication bias can skew medical literature and impact clinical decision-making, and I don't want to contribute to this problem.

In handling this situation, I would first carefully review the specific terms of the sponsorship agreement with my institution's research ethics board and legal team. I'd then attempt to negotiate with the pharmaceutical company to maintain publication independence while protecting their legitimate intellectual property interests. I would propose alternative arrangements, such as giving them a reasonable review period for proprietary information while maintaining my right to publish all results, regardless of outcome.

If the company remains inflexible about controlling publication rights, I would decline the offer and seek alternative funding sources. While this might delay my research, I believe maintaining scientific integrity is paramount. I would explore other options like government grants, academic institutions, or independent research foundations that don't impose such restrictions. I'd rather adjust the scope of my research or timeline than compromise on the fundamental principle of scientific transparency.

This experience would also motivate me to advocate for clearer institutional policies regarding industry sponsorship and to engage in broader discussions about maintaining research independence in an era of increasing private funding of medical research.

Use it for its structure. Interviewers can tell a memorized script, so tell your own story.

Keep going

• A fellow medical student is showing clear signs of burnout but is afraid to seek help due to the stigma surrounding mental health in medicine. How would you support your peer?
• How do you think your role as a physician fits in with your role as a member of the community?
• You are doing your rotations during medical school, and you see one of your closest friends in medical school cover up a medical error they made with a patient. What do you do?
• Medical school interview questions by type
• The full interview question bank